MS, MBA, Vice President and Head of the Pfizer Global Product Development Operations Center of Excellence
Pfizer
Rob Goodwin is Vice President and Head of the Pfizer Global Product Development Operations Center of Excellence, a discipline dedicated to servicing operational activities across Pfizer. In this role he is responsible for Standard Operating Procedures, Training, Contracting, Business Continuity Management, and Information Management across the development continuum for Clinical, Safety and Regulatory. In addition, he holds the executive relationships with the preferred Contract Research Organizations (CROs) as well as the analytics generation for reporting on performance metrics and cycle times across clinical studies. Mr Goodwin also has responsibilities for leading the advancement of clinical innovation.
From 2010 to 2015, Mr Goodwin served as the Vice President of Safety Evaluation and Reporting in Worldwide Safety and Regulatory where he was responsible for global Pharmacovigilance including Safety Case Processing, Medical Review, Safety Aggregate Reporting as well as Medical Authoring. Prior to that, he was Vice President of Operational Excellence and Business Innovation for Safety, Regulatory and Medical responsible for Pharmacovigilance Agreements, Contracts and Outsourcing, Project Management, Continuous Improvement, Metrics Reporting, and Safety and Regulatory Innovation. From 2005 to 2010, Mr. Goodwin was the Vice President and World-Wide Head of Global Clinical Data Services.
Mr. Goodwin has over 27 years of industry experience in statistics, SAS programming, data management, Electronic Data Capture (EDC), safety and strategic project management. Mr. Goodwin has led the EDC initiative at Pfizer and was recognized in 2002 with a Pfizer Presidents achievement and later in 2005 for his work for Process Harmonization and Optimization across Development Operations and Clinical. In February 2004, Mr. Goodwin was recognized in CIO Magazine as the Healthcare Industry winner for the Pfizer implementation of EDC. Mr. Goodwin is an executive Six Sigma Black Belt and has been a past member of PhRMA (Pharmaceutical Research and Manufacturers of America), past board member for CDISC (Clinical Data Interchange Standards Consortium). He is a current member of the Transcelerate operations board and a member of the Society for Clinical Data Management (SCDM) advisory board and a co-chair for the Vulcan HL7/Transcelerate research accelerator.
Mr Goodwin holds a BS in Psychology from Eastern Connecticut State University, a MS in Research, Measurement and Evaluation from Southern Connecticut State University and an MBA in Pharmaceutical and Chemical Studies.